Atea Pharmaceuticals, Inc. Common Stock AVIR
$5.12
-1.73%
at last close
Market Cap$417.87 million
P/E Ratio—
Div Yield—
Volume297.5K
52-Week Range
$2.78$6.45
Analyst Ratings
- Consensus
- Moderate Buy — 1 Buy · 1 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $8.50 (+66.0% upside)
Key Stats
- Today's Range
- $4.93 – $5.20
- 50-Day Range
- $3.82 – $5.90
- 52-Week Range
- $2.78 – $6.45
- Volume
- 297K shs
- Average Volume
- 264K shs
- Market Cap
- $417.87 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.05
- Price / Sales
- —
Short Interest
- Short Interest
- 0.39%
- Days to Cover
- 1.46
Financials (TTM)
- Revenue
- —
- Net Income
- $-165,289,000
- Net Margin
- —
- Return on Equity
- -80.96%
- Debt-to-Equity
- —
About Atea Pharmaceuticals, Inc. Common Stock
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Related Stocks
Compare head-to-head: AVIR vs LLY·AVIR vs JNJ·AVIR vs ABBV·AVIR vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.